PelD is required downstream of c-di-GMP for host specialization of Pseudomonas lurida.

Anna Czerwinski, Julia Löwenstrom, Sören Franzenburg, Espen Elias Groth, Nancy Obeng, Hinrich Schulenburg

Abstract read

In one paragraph

Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anna CzerwinskiDepartment of Evolutionary Ecology and Genetics, University of Kiel, 24118, Kiel, Germany.

Julia LöwenstromDepartment of Evolutionary Ecology and Genetics, University of Kiel, 24118, Kiel, Germany.

Sören FranzenburgInstitute of Clinical Molecular Biology, University of Kiel, 24118, Kiel, Germany.

Espen Elias GrothDepartment of Pneumology, LungenClinic Grosshansdorf, 22927, Großhansdorf, Germany.

Nancy Obeng *Department of Evolutionary Ecology and Genetics, University of Kiel, 24118, Kiel, Germany.

Hinrich Schulenburg *Department of Evolutionary Ecology and Genetics, University of Kiel, 24118, Kiel, Germany. hschulenburg@zoologie.uni-kiel.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe bacterial second messenger c-di-GMP is known to influence the formation of biofilms and thereby persistence of pathogenic and beneficial bacteria in hosts. A previous evolution experiment with Pseudomonas lurida MYb11, occasional symbiont of the nematode Caenorhabditis elegans, led to the emergence of host-specialized variants with elevated intracellular c-di-GMP. Thus far, the molecular underpinnings of c-di-GMP-mediated host specialization were unknown in this symbiosis. Therefore, the current study aimed at identifying candidate molecular processes by combining transcriptomic and functional genetic analyses.

resultsWe found that MYb11 host specialists differentially expressed genes related to attachment, motility and biofilm production, including pelD from the pel gene cluster. pelD deletion resulted in reduced intra-host competitive fitness, lower bacterial numbers in C. elegans and loss of biofilm biomass.

conclusionOur results identify pelD as a previously unknown key modulator of beneficial symbiont-host associations that acts downstream of c-di-GMP.

Indexed as

Bacterial ProteinsCaenorhabditis elegansCyclic GMPPseudomonasAnimalsBiofilmsGene Expression ProfilingGene Expression Regulation, BacterialMultigene FamilySymbiosisBacterial Proteinsbis(3',5')-cyclic diguanylic acidCyclic GMPBiofilmCaenorhabditis elegansc-di-GMPHost-microbe interactionpelDPseudomonas luridaSymbiosis

Identifiers

PMID40241006

DOI10.1186/s12866-025-03945-1

PMCPMC12001729

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.